Results 1 to 10 of about 49,657 (223)

Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer’s Disease Risk: A Retrospective Cohort Proof-of-Concept Study [PDF]

Pharmaceuticals
Brain somatic gene recombination (SGR) and the endogenous reverse transcriptases (RTs) that produce it have been implicated in the etiology of Alzheimer’s disease (AD), suggesting RT inhibitors as novel prophylactics or therapeutics.
Tiffany W. Chow, Mark Raupp, Matthew W. Reynolds, Siying Li, Gwendolyn E. Kaeser, Jerold Chun   +5 more
doaj   +2 more sources

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. [PDF]

J Acquir Immune Defic Syndr, 2022
Schürmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Däumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W.   +15 more
europepmc   +2 more sources

Nucleoside and non-nucleoside reverse transcriptase inhibitor drugs (NRTIs and NNRTIs) are capable of binding Chandipura virus polymerase protein (L) and inhibit virus replication. [PDF]

Virusdisease
Mandal D, Pandey D, Sarkar DP, Kumar M.
europepmc   +3 more sources

Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.

J Mater Chem B, 2023
Liu C, Hern FY, Shakil A, Temburnikar K, Chambon P, Liptrott N, McDonald TO, Neary M, Flexner C, Owen A, Meyers CF, Rannard SP.   +11 more
europepmc   +3 more sources

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009) [PDF]

, 2013
Background:A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of drug resistance, particularly from individuals who are HIV-infected but unaware of their status.
Barbara Mensch, Cliff Kelly, Gita Ramjee, John W. Mellors, Kailazarid Gomez, Krista Eskay, Lydia Soto-Torres, on behalf of the IPTc Taskforce, Pamina Gorbach, Photini Kiepiela, Shayhana Ganesh, Stephanie Horn, Urvi M. Parikh   +12 more
core   +34 more sources

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor

Тонкие химические технологии, 2011
In recent years, various approaches to the prodrug design on the basis of anti-HIV active nucleoside compounds used in the therapy are intensively investigated.
N. S. Shastina, E. O. Baranova, L. N. Dyakova, D. V. Lonshakov, V. I. Shvets   +4 more
doaj   +1 more source

Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

Frontiers in Molecular Biosciences, 2022
Reverse transcriptase (RT) from the human immunodeficiency virus continues to be an attractive drug target for antiretroviral therapy. June 2022 will commemorate the 30th anniversary of the first Human Immunodeficiency Virus (HIV) RT crystal structure ...
Kathleen M. Frey, Nicole Bertoletti, Albert H. Chan, Joseph A. Ippolito, Mariela Bollini, Krasimir A. Spasov, William L. Jorgensen, Karen S. Anderson, Karen S. Anderson   +8 more
doaj   +1 more source

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. [PDF]

PLoS ONE, 2012
IntroductionCurrent Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two ...
Filipa Aragão, José Vera, Inês Vaz Pinto   +2 more
doaj   +1 more source

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Viruses, 2022
Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase ...
Maria E. Cilento, Yee Tsuey Ong, Philip R. Tedbury, Stefan G. Sarafianos   +3 more
doaj   +1 more source

Effect of Antiretroviral Therapy on Circulating Lipid Levels in Human Immunodeficiency Virus Infected Patients: A Cross-sectional Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: The antiretroviral drugs have improved the quality and extent of life of Human Immunodeficiency Virus (HIV) infected patients, yet like any other long-term medication, these are known to cause several adverse effects.
RN Devaki, Hasit Kumar D Lad, Rana Neetaben Maheshchandra, N Chandrika   +3 more
doaj   +1 more source